UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): September 22, 2010 (September 22, 2010)
VALEANT PHARMACEUTICALS INTERNATIONAL
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
1-11397
|
|
33-0628076 |
(State or Other Jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer Identification |
of Incorporation)
|
|
|
|
Number) |
One Enterprise
Aliso Viejo, California 92656
(Address of principal executive offices, including zip code)
(949) 461-6000
(Registrants telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item 8.01 Other Events.
On
September 22, 2010, Valeant Pharmaceuticals International, a Delaware corporation (Valeant),
issued a press release announcing the pricing of $500 million aggregate principal amount of its
6.75% Senior Notes due 2017 and $700 million aggregate principal amount of its 7.00% Senior Notes
due 2020. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein
by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
|
|
|
Exhibit |
|
|
Number |
|
Description of Exhibit |
99.1
|
|
Press Release dated
September 22, 2010. |